Login to Your Account

Curevac's prostate cancer vaccine falls short in phase IIb study

By Michael Fitzhugh
Staff Writer

Thursday, January 12, 2017

Curevac AG's mRNA-based prostate cancer vaccine CV9104, long its lead candidate, failed to meet the primary endpoint of improving overall survival during a phase IIb trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription